A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study

Thrombosis Research

Volumn 125, Issue 4, 2010, Pages 309-314

  Palmerini, Tullio ^a   Barozzi, Chiara ^a   Tomasi, Luciana ^a   Sangiorgi, Diego ^a   Marzocchi, Antonio ^a   De Servi, Stefano ^b   Ortolani, Paolo ^a   Bacchi Reggiani, Letizia ^a   Alessi, Laura ^a   Lauria, Giulia ^a   Bassi, Mirna ^a   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Ospedale Civile   (Italy)

Author keywords

Acute myocardial infarction; Antiplatelet drugs; Coronary angioplasty

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; WARFARIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

ANTERIOR WALL MYOCARDIAL INFARCTION; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; HUMANS; MICROFILAMENT PROTEINS; MYOCARDIAL INFARCTION; PHOSPHOPROTEINS; PLATELET AGGREGATION; TICLOPIDINE;

EID: 77949568294     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.06.016     Document Type: Article

References (25)

1. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 9281 (2001) 527-533
2. Boneu B., and Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 76 6 (1996) 939-943
3. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 14 (2007) 1505-1516
4. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 23 (2003) 2908-2913
5. Angiolillo D.J., Bernardo E., Sabate M., Jimenez-Quevedo P., Costa M.A., Palazuelos J., et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50 16 (2007) 1541-1547
6. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46 10 (2005) 1827-1832
7. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 25 (2004) 3171-3175
8. Gawaz M., Neumann F.J., Ott I., Schiessler A., and Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93 2 (1996) 229-237
9. Ardissino D., Merlini P.A., Gamba G., Barberis P., Demicheli G., Testa S., et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 93 9 (1996) 1634-1639
10. Spaulding C., Henry P., Teiger E., Bratt K., Bramucci E., Carrie D., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 11 (Sep 14 2006) 1093-1104
11. Wiviott S.D., Braunwald E., McCabe C.H., Horvath I., Keltai M., Herrman J.P., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet (2008)
12. Blindt R., Stellbrink K., de Taeye A., Muller R., Kiefer P., Yagmur E., et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 98 6 (2007) 1329-1334
13. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 6 (2007) 708-716
14. Palmerini T., Coller B.S., Cervi V., Tomasi L., Marzocchi A., Marrozzini C., et al. Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. J Am Coll Cardiol 44 8 (2004) 1570-1577
15. von Beckerath N., Kastrati A., Wieczorek A., Pogatsa-Murray G., Sibbing D., Graf I., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28 15 (2007) 1814-1819
16. Plosker G.L., and Lyseng-Williamson K.A. Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 67 4 (2007) 613-646
17. Geiger J., Teichmann L., Grossmann R., Aktas B., Steigerwald U., Walter U., et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 51 6 (2005) 957-965
18. Geisler T., Grass D., Bigalke B., Stellos K., Drosch T., Dietz K., et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 6 1 (Jan 2008) 54-61
19. Ellis S.G., Colombo A., Grube E., Popma J., Koglin J., Dawkins K.D., et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3, 445 patients followed for up to 3 years. J Am Coll Cardiol 49 10 (Mar 13 2007) 1043-1051
20. Coller B.S. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arterioscler Thromb Vasc Biol 25 4 (Apr 2005) 658-670
21. Barron H.V., Cannon C.P., Murphy S.A., Braunwald E., and Gibson C.M. Association between white cell blood count, epicardial blood flow, myocardial perfusion and clinical outcomes in the setting of acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10 substudy. Circulation 102 (2000) 2329-2334
22. Barron H.V., Harr S.D., Radford M.J., Wanh Y., and Krumholz H.M. The association between white blood cell count and acute myocardial infarction mortality in patients > or = 65 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol 38 (2001) 1654-1661
23. Li N., Hu H., Lindqvist M., Wikstrom-Jonsson E., Goodall A.H., and Hjemdahl P. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 20 12 (Dec 2000) 2702-2708
24. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., and Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104 13 (Sep 25 2001) 1533-1537
25. Mickelson J.K., Lakkis N.M., Villarreal-Levy G., Hughes B.J., and Smith C.W. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol. 28 2 (1996) 345-353